15 results about "Cholesterol derivatives" patented technology

To provide ink for inkjet printer which is capable of marking under a normal temperature environment by using an inkjet printer, and applicable to marking on refrigerated products or frozen products, and a temperature indicator using the ink.SOLUTION: Ink for inkjet printer according to the present invention is ink in which temperature indicator is dissolved into solvent, where the temperature indicator contains leuco dye, developer and decoloring agent, the decoloring agent is a mixture of a plurality of kinds of cholesterol derivative, each of the plurality of kinds of cholesterol derivative has predetermined polar group, polar site and / or polar structure by 1 or more and 3 or less, and the solvent is a mixture of main solvent having relatively high volatility and sub solvent having relatively low volatility.SELECTED DRAWING: Figure 2

This invention discloses a cholesterol derivative, its preparation method, and its applications. The structure is shown in Formula I, where the definitions of each substituent are as described in the specification and claims. The compound of this invention can effectively antagonize the FXR receptor.

The invention provides ski wax compositions comprising a lipid component which is a cholesterol or a cholesterol derivative, a fatty acid or salt of a fatty acid, a diglyceride, or a combination thereof. It further provides ski wax compositions comprising squalene or a squalene derivative. The ski wax compositions according to the invention can be used as a glide wax or grip wax and may be applied directly to the base of a ski or to a ski skin.

The application belongs to the technical field of medical intermediates, and discloses application of a cholesterols derivative in preparation of a diabetes drug. It is found by the application that the cholesterols derivative has good alpha-glucosidase inhibiting activity by using an in-vitro pharmacological activity model for evaluation, and has potential to be developed into a new type of diabetes prevention or treatment drug.

The present invention discloses a dynamic thermochromic luminescent material and method. The dynamic thermochromic luminescent material is obtained by inducing coordination interaction between a cholesterol derivative dispersed in an organic solvent and ZnCl2. The method comprises: dispersing the cholesterol derivative in the organic solvent, ultrasonically treating the mixture to obtain a clear and transparent solution, adding ZnCl2 in an amount of 0.1-1.5 molar equivalents of the cholesterol derivative to the solution, and ultrasonically cleaning the solution in an ultrasonic cleaner to obtain a series of dynamic thermochromic luminescent materials H1 with cyan-green fluorescence; taking the dynamic thermochromic luminescent material H1 and subjecting it to the following heat treatment: constant-temperature heating at 50-80°C for about 15-25s, and then immediately placing the solution in an ultrasonic cleaner filled with ice water and ultrasonicating the solution to obtain a dynamic thermochromic luminescent material H2 with blue fluorescence. In summary, the present invention provides a switchable luminescent material responsive to temperature stimulation. The material and method of the present invention can be applied to information encryption.

The invention discloses a 7-site amino-acid ester-cholesteric derivative, the chemical structure of which is shown in the following formula: wherein the 7-site amino-acid ester-cholesteric derivative has an inhibition effect on human breast cancer cells, human ovarian cancer cells, human breast duct cancer cells and human cervical cancer cells, and can be used for preparing antitumor drugs.

The invention relates to the field of synthesis of organic fluorescent dyes, and discloses a conjugate of indocyanine green and cholesterol as well as synthesis and application of the conjugate. The conjugate is formed by connecting an indocyanine green derivative and a cholesterol derivative through an amido bond; the indocyanine green derivative is ICG-R-COOH; iCG is indocyanine green, R is-(CH2) nH. [I-], n is an integer of 1-6, or R is-(CH2) mSO3-, and m is 3 or 4; and the cholesterol derivative is cholesterole-NH2, beta-sitosterole-NH2, stigmasterole-NH2 or ergosterole-NH2. The invention also discloses a preparation method of the cholesterol derivative. The lipidosome constructed by the conjugate is high in stability, good in dispersity and strong in NIR-II fluorescence, the blood vessel and tumor imaging contrast ratio and definition under a 1300 nm near-infrared imaging window are superior to those of lipidosome constructed by commercial ICG, more excellent diagnosis and treatment performance is shown, and wide application prospects are achieved.

The present invention discloses a zwitterionic polypeptide lipid molecule and its application, belonging to the technical field of drug delivery system. The general formula of the zwitterionic polypeptide lipid molecule is R-(E-K) n , wherein R is a fatty acid, a diglyceride derivative, or a cholesterol derivative, E is glutamic acid, K is lysine, and n is an integer between 5 and 20. The zwitterionic polypeptide lipid molecule is formed by bonding a fatty acid, a diglyceride derivative, or a cholesterol derivative to an EK polypeptide. It can be used as an alternative component to PEG lipids in lipid nanoparticles, and can be combined with cationic lipids, phospholipids, and cholesterol to form lipid nanoparticles with the ability to deliver mRNA to cells and animals. Experimental verification shows that compared with PEG lipids, the lipid nanoparticles composed of the zwitterionic polypeptide lipid molecules provided by the present invention have improved cell transfection ability in vivo and in vitro, improved the delivery efficiency of the lipid nanoparticles, and have no obvious cytotoxicity.

The invention relates to the technical field of nano-drugs, in particular to a glucocorticoid nano-emulsion for treating sepsis. The sialic acid-cholesterol derivative modified glucocorticoid nano-emulsion provided by the invention can remarkably improve the survival rate and the life quality of mice when being used for treating sepsis, and in a sepsis re-challenge pharmacodynamics experiment, under the condition that secondary drug treatment is not carried out, the survival rate of survived mice is high, and the survival rate of the survived mice is high. The risk of reinfection is greatly reduced, and guiding significance is provided for solving the problem that the death rate of sepsis survivors is high after the sepsis survivors are discharged from hospital clinically; meanwhile, the sialic acid-cholesterol derivative modified glucocorticoid nanoemulsion disclosed by the invention can also reduce the risk of secondary infection of diseases caused by pathogens containing LPS antigens in the organism.

The invention relates to the technical field of nano-drugs, in particular to sialic acid modified ibrutinib phospholipid complex nanoparticles capable of being used for treating sepsis. The sialic acid modified ibrutinib phospholipid complex nanoparticle prepared by the invention comprises ibrutinib, egg yolk phosphatidyl glycerol and a sialic acid-cholesterol derivative, and the nanoparticle can obviously improve the accumulation of a preparation at an inflammation part and the targeting of the preparation on inflammation-related macrophages; the BTK inhibitor has the advantages that the BTK inhibitor can be used for treating sepsis, so that the sepsis treatment effectiveness and safety of the BTK inhibitor are greatly improved, more importantly, sepsis survivor mice can be helped to relieve the immunosuppression state, strong immune memory is generated, the reinfection risk is greatly reduced, and the BTK inhibitor has guiding significance in solving the problem that the death rate of sepsis survivors is relatively high after the sepsis survivors are discharged from hospitals clinically; meanwhile, the sialic acid modified ibrutinib phospholipid complex nanoparticles can also reduce the risk of secondary infection of diseases caused by pathogens containing LPS antigens by the organism.

The invention discloses application of a sialic acid modified nano preparation in preparation of a continuous low-dose drug delivery system, and belongs to the technical field of medicine, sialic acid is a sialic acid-cholesterol derivative, according to a continuous low-dose drug delivery scheme, the drug delivery concentration is 1 / 3-1 / 10 of the maximum tolerated dose, and the drug delivery concentration is 1 / 3-1 / 10 of the maximum tolerated dose. The sialic acid modified nano preparation is a sialic acid modified epirubicin liposome. Experiments prove that a continuous low-dose administration scheme of the sialic acid modified nano preparation can remarkably reduce liver and spleen accumulation, improve the targeting efficiency of a tumor site and maintain the blood concentration for a long time. The invention provides a solution for solving the problem that the curative effect of continuous low-dose administration of the PEGylated nano preparation is influenced by the anti-PEG antibody.

Targeted liposomes for delivery of protein degrading agents. In one embodiment, the targeting liposome includes a phospholipid, cholesterol or a cholesterol derivative, a PEG lipid, a targeting lipid, and a protein degradation agent. In other embodiments, the targeted liposomes include phospholipids, cholesterol or cholesterol derivatives, PEG lipids, targeted lipids, and a protein degrading agent-ligase complex. Also provided are kits for the preparation of targeted liposomes of protein degradation agents and / or protein degradation agent-ligase complexes. Methods of making such targeted liposomes are also provided.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a cholesterol derivative as well as a preparation method and application thereof. The chemical structural formula of the cholesterol derivative is shown in the specification. According to the cholesterol derivative, effective loading of mRNA can be achieved, the encapsulation efficiency of the cholesterol derivative to mRNA is 80% or above, compared with natural cholesterol, the cholesterol derivative has higher delivery efficiency when used for nucleic acid drug delivery, and the cholesterol derivative has good biocompatibility and pharmaceutical properties and can be used for preparing a nucleic acid drug. Good application prospects are realized in the field of development of drug delivery systems and drug preparations.

The invention relates to a method for preparing cells overexpressing exogenous genes through electrotransfection, which comprises the following steps: treating the cells with a cell electrotransfection pretreatment reagent before electrotransfection, and the cell electrotransfection pretreatment reagent contains cholesterol derivatives. The invention also relates to the exogenous gene overexpressed cell prepared by the method, application of the cell electrotransfection pretreatment reagent in preparation of the exogenous gene overexpressed cell, and a cell electrotransfection kit. The cell electrotransfection kit comprises a cell electrotransfection medium component and a cell treatment component. The cell treatment component comprises a cholesterol derivative. The method provided by the invention can greatly improve the survival rate of cells after electrotransfection and the proportion and quantity of cells with positive exogenous gene expression.

The invention belongs to the technical field of nucleic acid vaccines, and particularly relates to an srRNA vaccine targeting multiple mutant p53 proteins, a construction method and application. The self-replicating srRNA vaccine comprises sialic acid modified lipid nanoparticles and srRNA, and the srRNA is encapsulated in the sialic acid modified lipid nanoparticles; the srRNA comprises a double-chain tandem micro-gene, and is obtained by carrying out PCR (Polymerase Chain Reaction) on a coding sequence which is formed by sequentially connecting a plurality of antigen extraction units containing p53 protein mutation sites in series and converting the antigen extraction units; the sialic acid modified lipid nanoparticles are prepared from the following raw materials: an ionizable lipid, distearoyl phosphatidylcholine, cholesterol, a sialic acid cholesterol derivative SA-AE-AC-CH and dimyristoyl glycerol-polyethylene glycol 2000. The problems that a traditional mRNA vaccine is short in duration time and inaccurate in targeting are solved.